NASDAQ:CBAT

CBAK Energy Technology, Inc. (NASDAQ: CBAT) Q1 2026 Financials: Revenue Growth Amidst EPS Miss

Font: Financial Modeling Prep  • May 18, 2026

Market Chart
  • CBAK Energy Technology, Inc. (NASDAQ: CBAT) reported a Q1 2026 EPS of -$0.08, missing analyst estimates of -$0.03, indicating a net loss for the period.
  • Despite slightly missing revenue estimates, CBAK Energy Technology, Inc. achieved substantial 99.3% year-over-year revenue growth, reaching $69.62 million.
  • The Light Electric Vehicles (LEV) sector was a significant growth driver, with its revenue surging by 441.6% to $15.41 million, reflecting strong market demand.

CBAK Energy Technology, Inc. (NASDAQ: CBAT) is a prominent lithium-ion battery manufacturer based in China. The company develops and produces batteries for various applications, including electric vehicles and energy storage. On May 18, 2026, CBAK Energy Technology, Inc. reported its financial results for the first quarter of the year, providing insight into its recent performance.

The company announced an earnings per share (EPS) of -$0.08. This figure missed the analyst consensus estimate of -$0.03. EPS indicates a company's profit per outstanding share of stock. A negative EPS, like CBAK Energy Technology, Inc.'s, means the company incurred a net loss for the period rather than a profit.

CBAK Energy Technology, Inc.'s revenue for the quarter was $69.62 million, which fell slightly short of the estimated $70.23 million. While this missed expectations, the company's overall sales performance showed significant growth compared to the previous year. This highlights a major increase in customer demand and sales volume.

As highlighted by GlobeNewswire, consolidated net revenues saw a substantial 99.3% year-over-year increase from $34.94 million. This was driven by expanded production capacity. The Light Electric Vehicles (LEV) sector was a standout, with its revenue surging by 441.6% to $15.41 million from $2.84 million a year prior.

The company's unprofitability is also reflected in its negative Price-to-Earnings (P/E) ratio of -3.95. The P/E ratio compares a company's stock price to its earnings. In contrast, its Price-to-Sales ratio is 0.29, which compares the stock price to its revenues.

Market Overview
VRAX
Virax Biolabs Group Limited
$0.24
53.09%
WGRX
Wellgistics Health, Inc.
$0.17
108.38%
AIM
AIM ImmunoTech Inc.
$0.41
61.26%
SBFM
Sunshine Biopharma, Inc.
$0.51
79.51%
SOXS
Direxion Daily Semiconductor Bear 3X ETF
$9.95
7.80%
TZA
Direxion Daily Small Cap Bear 3X ETF
$5.05
1.81%
PMI
Picard Medical, Inc.
$0.17
7.06%
GOVX
GeoVax Labs, Inc.
$2.21
79.67%
NXXT
NextNRG Inc.
$0.41
46.22%
CREG
Smart Powerr Corp.
$0.62
30.59%